Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Other causes of PAA include pulmonary hypertension, vasculitis, syphilis, tuberculosis, left-to-right shunts, pulmonary valve stenosis with post-stenotic dilatation, vasa vasorum dysfunction, trauma, ...

TITLE: Isolated Patent Ductus Arteriosus in an Elderly Female, Aged 65 Years—A Case Report AUTHORS: Ramachandran Muthiah KEYWORDS: Adult Ductus, Pulmonary Hypertension, Pulmonary Vasodilators, ...

Context Knowledge gaps exist on the incidence and risk factors for developing pulmonary hypertension (PH) in preterm infants with bronchopulmonary dysplasia (BPD) and its impact on outcomes. Objective ...

References: Backes CH, Hill KD, Shelton EL, et al. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022;11 (17):e025784 ...

There is a class IIb recommendation to consider closure of PDA if pulmonary artery systolic pressure is ≥50% systemic or pulmonary vascular resistance is greater than one-third systemic. 2 Complete ...